Efficacy and safety of the compound Chinese medicine SaiLuoTong in vascular dementia: A randomized clinical trial. Issue 1 (22nd March 2018)

• Record Type: Journal Article
• Authors: Jia, Jianping; Wei, Cuibai; Chen, Shuoqi; Li, Fangyu; Tang, Yi; Qin, Wei; Shi, Lu; Gong, Min; Xu, Hui; Li, Fang; He, Jia; Song, Haiqing; Yang, Shanshan; Zhou, Aihong; Wang, Fen; Zuo, Xiumei; Chu, Changbiao; Liang, Junhua; Jia, Longfei; Gauthier, Serge
• Is Part Of: Alzheimer's & dementia. Volume 4:Issue 1(2018)
• Page Start: 108
• Page End: 117
• Publication Date: 2018-03-22
• Subjects: Vascular dementia -- Clinical trial -- Compound Chinese medicine -- SaiLuoTong/SLT; Dementia -- Periodicals; Dementia -- Treatment -- Periodicals; Alzheimer's disease -- Treatment -- Periodicals; Alzheimer's disease -- Periodicals; 616.831
• DOI: 10.1016/j.trci.2018.02.004
• Languages: English
• ISSNs: 2352-8737

Abstract

Abstract: Introduction: No licensed medications are available to treat vascular dementia (VaD). Methods: Patients were randomly assigned to experimental groups (SaiLuoTong [SLT] 360 or 240 mg for groups A and B for 52 weeks, respectively) or placebo group (SLT 360 mg and 240 mg for group C only from weeks 27 to 52, respectively). Results: Three hundred twenty‐five patients were included in final analysis. At week 26, the difference in VaD Assessment Scale–cognitive subscale scores was 2.67 (95% confidence interval, 1.54 to 3.81) for groups A versus C, and 2.48 (1.34 to 3.62) for groups B versus C (both P < .0001). However, at week 52, no difference was observed among the groups on the VaD Assessment Scale–cognitive subscale ( P = .062) because of the emerging efficacy of SLT in placebo beginning at week 27. Discussion: This study suggests that SLT is effective for treatment of VaD, and this compound Chinese medicine may represent a better choice to treat VaD.